Aziende Chimiche Riunite Angelini Francesco A.c.r.a.f. S.p.a.

Giuseppe Biondi

Angelo Guglielmotti

Giorgina Mangano

Tommaso Iacoangeli

Marcello Marchetti

Giovanni Battista Ciottoli

Beatrice Garrone

Vincenzo Russo

Elisa Liberati

Alessandro Ble'

The present invention relates to a pharmaceutical composition comprising a combination of 1-benzyl-3-hydroxymethylindazole derivative, a pressure lowering agent selected from ACE-inhibitors, renin inhibitors, ARBs and CCBs, and/or a cholesterol lowering agent selected from statin derivatives. The combination showed an additive and synergistic activity in reducing MCP-1 levels, thus significantly improving inflammatory response inhibition and consequently reducing complications occurring in patients suffering from inflammatory diseases.

Pharmaceutical composition for the treatment of MCP-1 mediated inflammatory diseases

The present invention relates to a food formulation for the controlled release of glucose comprising glycogen and at least one other edible component, as well the use of glycogen for its preparation.

Food formulation comprising glycogen

A method of treating insulin resistance, obesity and metabolic syndrome by administering an indazolemethoxyalkanoic acid as described herein.

Use of an indazolemethoxyalkanoic acid for reducing triglyceride, cholesterol and glucose levels

A process of production of trazodone or trazodone hydrochloride that comprises: (a) preparing an organic phase comprising trazodone in at least one organic solvent; (b) preparing an aqueous phase comprising at least one basic compound; (c) mixing said aqueous phase with said organic phase; (d) heating at a temperature of at least 40&#xb0; C. for at least 30 minutes; (e) recovering said trazodone; and, optionally, (f) treating said trazodone with hydrochloric acid to obtain trazodone hydrochloride. Trazodone or trazodone hydrochloride comprising less than 15 ppm of alkylating substances, and a pharmaceutical composition comprising said trazodone hydrochloride.

Trazodone and trazodone hydrochloride in purified form

Use of a compound of formula (I) in which R, R' and R&#x2033; have the meanings given in the description, optionally in the form of a salt thereof with a pharmaceutically acceptable organic or mineral base, to prepare a pharmaceutical composition for reducing the blood triglyceride, cholesterol and glucose levels. 

A process of production of trazodone or trazodone hydrochloride that comprises the steps of: (a) preparing an organic phase comprising trazodone in at least one organic solvent; (b) preparing an aqueous phase comprising at least one basic compound; (c) mixing said aqueous phase with said organic phase; (d) heating at a temperature of at least 40&#xb0; C. for at least 30 minutes; (e) recovering said trazodone; and, optionally, (f) treating said trazodone with hydrochloric acid to obtain trazodone hydrochloride. Trazodone or trazodone hydrochloride comprising less than 15 ppm of alkylating substances, and a pharmaceutical composition comprising said trazodone hydrochloride. 

Growing community of inventors

Castel Gandolfo, Italy

Giuseppe Biondi